Of interest, the use of a monoclonal antibody targeting BDCA2 showed improvement of skin lesions in systemic lupus erythematosus (63), however no preclinical studies have been performed so far to evaluate the efficacy of such strategy in vitiligo. Here, CLEC4C is linked to vitiligo.